Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 5454-year-old man with acute myeloid leukemia is admitted to the hospital with a fever of 39.4∘C39.4^\circ C (102.9∘F102.9^\circ F) and chills. He received induction chemotherapy 1010 days ago. His blood pressure is 110/70110/70 mmHg and heart rate is 112112/min. Laboratory studies show an absolute neutrophil count of 200/μL200/\mu L. He has an indwelling central venous catheter in place. Arrange the following steps in the correct chronological sequence for the standard diagnostic evaluation, therapeutic intervention, and longitudinal monitoring of this patient's high-risk febrile neutropenia.

  1. 1Obtain at least two sets of blood cultures (one from the central venous catheter and one from a peripheral vein).
  2. 2Administer an empiric broad-spectrum antipseudomonal beta-lactam antibiotic.
  3. 3Monitor clinical response and evaluate preliminary microbiological data at 4848 to 7272 hours.
  4. 4Initiate empiric antifungal therapy if profound neutropenia and fever persist beyond 44 to 77 days.

Answer

The correct sequence is to first obtain blood cultures, immediately follow with empiric broad-spectrum antipseudomonal antibiotics, monitor clinical response and cultures at 4848 to 7272 hours, and finally initiate empiric antifungal therapy if fever and severe neutropenia persist beyond 44 to 77 days.
High-risk febrile neutropenia is a medical emergency requiring a strict, standardized sequential approach. It begins with immediate acquisition of blood cultures (both peripheral and central) to identify the pathogen. Because these patients can deteriorate rapidly from overwhelming bacterial sepsis, this is followed immediately by the administration of empiric broad-spectrum antibiotics covering Pseudomonas aeruginosa (e.g., cefepime). Once therapy is initiated, the patient must be monitored closely, with a structured clinical and microbiological reassessment at the 4848- to 7272-hour mark. If the patient remains persistently febrile and profoundly neutropenic beyond 44 to 77 days without an identified source, occult fungal infection becomes highly probable, and empiric antifungal therapy (e.g., an echinocandin or azole) is added to the regimen.

Step-by-Step Solution

1
Obtain blood cultures before initiating any antibiotics.
Maximizes the chance of identifying the causative bacterial pathogen.
Antibiotic administration prior to culture collection drastically reduces microbiological yield and compromises targeted therapy later.
2
Administer empiric broad-spectrum antipseudomonal antibiotics.
Provides immediate coverage against high-mortality pathogens like Pseudomonas aeruginosa.
Neutropenic patients lack the normal inflammatory immune response to contain infections, leading to rapid progression to septic shock if untreated.
3
Reassess clinical status and preliminary culture data at 4848 to 7272 hours.
Determines if current empiric therapy is effective or if source control or antibiotic modifications are needed.
It takes approximately 4848 to 7272 hours for most standard bacterial cultures to yield preliminary results and for clinical defervescence to occur on appropriate therapy.
4
Add empiric antifungal therapy at 44 to 77 days if the patient is still febrile.
Treats potential occult invasive fungal infections.
Prolonged severe neutropenia accompanied by persistent fever unresponsive to broad-spectrum antibacterial agents is a classic presentation for invasive fungal disease.

Key Concept

Standard management timeline and protocol for high-risk febrile neutropenia.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic